New Weight-Loss Pill Approved for Sale in Israel

A new once-daily oral weight-loss medication, Orforglipron (Foundayo), will be available in Israel starting September 15. Developed by Eli Lilly, the drug mimics the action of GLP-1 hormones, which help regulate blood sugar and slow stomach emptying, similar to injectable weight-loss drugs like Ozempic and Wegovy. Orforglipron is indicated for adults with obesity or overweight conditions accompanied by at least one comorbidity, to be used in conjunction with a reduced-calorie diet and increased physical activity.

Israel is the fourth country globally to commercially offer the drug, following its approval by the U.S. FDA and availability in the United States, the United Kingdom, and the United Arab Emirates. The medication will be sold in six dosages, with prices ranging from approximately 691.59 NIS for 0.8 mg and 2.5 mg doses to 1,146.46 NIS for 14.5 mg and 17.2 mg doses.

Clinical trials demonstrated significant weight reduction, with the highest dose leading to an average loss of 12.4% of body weight (around 12.4 kg) in adults with overweight or obesity. In a separate study involving type 2 diabetes patients with excess weight, Orforglipron also showed a statistically significant reduction in the combined risk of cardiovascular death and heart attack compared to a placebo. Additional metabolic benefits observed included a reduction in waist circumference, lower LDL cholesterol, decreased blood pressure, and a modest decrease in HbA1c levels for diabetic patients.

Eli Lilly stated that Orforglipron's safety profile is comparable to other GLP-1 agonists, with gastrointestinal side effects such as nausea, vomiting, and diarrhea being the most common, particularly at the start of treatment. Approximately 10.6% of participants in high-dose trials discontinued the medication due to these side effects.